Topi A Tervonen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Topi A Tervonen has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Jeroen Pouwels
2 shared publications- Juha Klefström
University of Helsinki
2 shared publications - Pauliina M. Munne
Cancer Cell Circuitry Laboratory, Translational Cancer Medicine, Medical Faculty, University of Helsinki. P.O. Box 63, Haartmaninkatu 8, FI-00014 Helsinki, Finland
2 shared publications - Aino Peura
Cancer Cell Circuitry Laboratory, Translational Cancer Medicine Research Program, Research Programs Unit, & Medicum, University of Helsinki, Helsinki, Finland
1 shared publication - Andrei Goga
Department of Cell & Tissue Biology, University of California, San Francisco
1 shared publication - Antti O Hiltunen1 shared publication
Latest Publications
- Open Access
Microtubule Inhibition Triggers MYC-Mediated Immunogenic Cell Death in Breast Cancer
Oncogenic MYC promotes cancer cell proliferation, metabolism, and death, while also driving immunosuppression in the tumour microenvironment, complicating immune-based therapies. To counter MYC-driven immune evasion while leveraging MYC-dependent synthetic lethality (MYC-SL), we identified microtubule-targeting agents, including eribulin, as potent inducers of immunogenic cell death in MYC high triple-negative breast cancer (TNBC). A screen of 528 oncology compounds using damage-associated molecular pattern (DAMP) reporters revealed that microtubule inhibitors induced key DAMPs, including HMGB1 secretion, calreticulin exposure, and double-stranded DNA release, leading to gasdermin-E associated cell death in MYC high TNBCs. Immune cell co-culture assays showed immune activation, and patient-derived explant cultures confirmed pro-inflammatory cytokine responses. In vivo, cell-free media from eribulin-treated MYC high murine TNBCs enhanced tumour protection in vaccination models compared to MYC-knockdown controls, linking MYC-dependent DAMP release to immunogenicity. These findings highlight a dual-function therapeutic strategy: agents that selectively induce MYC-dependent immunogenic cell death can provide both targeted cytotoxicity and local immune stimulation, thereby addressing a key limitation of conventional chemotherapeutics, offering a new approach for MYC-driven cancers.
Open AccessMicrotubule Inhibition Triggers MYC-Mediated Immunogenic Cell Death in Breast Cancer
Oncogenic MYC promotes cancer cell proliferation, metabolism, and death, while also driving immunosuppression in the tumour microenvironment, complicating immune-based therapies. To counter MYC-driven immune evasion while leveraging MYC-dependent synthetic lethality (MYC-SL), we identified microtubule-targeting agents, including eribulin, as potent inducers of immunogenic cell death in MYC high triple-negative breast cancer (TNBC). A screen of 528 oncology compounds using damage-associated molecular pattern (DAMP) reporters revealed that microtubule inhibitors induced key DAMPs, including HMGB1 secretion, calreticulin exposure, and double-stranded DNA release, leading to gasdermin-E associated cell death in MYC high TNBCs. Immune cell co-culture assays showed immune activation, and patient-derived explant cultures confirmed pro-inflammatory cytokine responses. In vivo, cell-free media from eribulin-treated MYC high murine TNBCs enhanced tumour protection in vaccination models compared to MYC-knockdown controls, linking MYC-dependent DAMP release to immunogenicity. These findings highlight a dual-function therapeutic strategy: agents that selectively induce MYC-dependent immunogenic cell death can provide both targeted cytotoxicity and local immune stimulation, thereby addressing a key limitation of conventional chemotherapeutics, offering a new approach for MYC-driven cancers.
- Open Access
- 13 September 2021
- Published by Springer Nature in EMBO Reports
- Vol. 22 (11) , e52532
Hepsin regulates TGFβ signaling via fibronectin proteolysis
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- 13 September 2021
- Published by Springer Nature in EMBO Reports
- Vol. 22 (11) , e52532
Open AccessHepsin regulates TGFβ signaling via fibronectin proteolysis
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.